



Marinus Pharmaceuticals  
Investor Relations Department  
170 N. Radnor Chester Road,  
Suite 250  
Radnor, PA 19087-5279  
United States

Visit IR website [↗](#)  
Sign-up for Email alerts [↗](#)

#### NASDAQ: MRNS

Last Trade:	1.17
Trade Time:	4:00 PM ET May 23, 2017
Change:	0.01 <span style="color: green;">▲</span> (+0.862%)
Day Range	1.13 - 1.19
52-Week Range	0.82 - 6.15
Volume	102,055


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Marinus is committed to maximizing shareholder value by developing and commercializing ganaxolone for treatment of drug-resistant seizures in both the hospital and home settings.

... [\(more\)](#)

## Stock Performance



### Press Releases [\[ View all \]](#)

- May 1, 2017*  
[Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2017 Financial Results](#)
- Apr 18, 2017*  
[Marinus to present Ganaxolone DATA at American academy of neurology annual meeting](#)
- Apr 11, 2017*  
[Dr. Lorianne K. Masuoka Joins Marinus Pharmaceuticals as Chief Medical Officer](#)
- Apr 10, 2017*  
[Ganaxolone IV Clinical Data Presented at Leading International Status Epilepticus Medical Conference](#)
- Mar 15, 2017*  
[Marinus Pharmaceuticals to Present at Oppenheimer Healthcare Conference](#)

### Upcoming Events [\[ View all \]](#)

- Jun 2–3, 2017*  
[CDKL5 Congress](#)
- Jun 6–9, 2017*  
[Jefferies Global Healthcare Conference](#)
- Financials & Filings [\[ View all \]](#)**
  - [First Quarter Financial Results](#)
- Mar 13, 2017*  
[Annual Report \(10-K\)](#)
- Mar 16, 2017*  
[Proxy Statement \(DEF 14A\)](#)
- May 1, 2017*  
[Quarterly Report \(10-Q\)](#)
- Nov 8, 2016*  
[Quarterly Report \(10-Q\)](#)
- Aug 9, 2016*  
[Quarterly Report \(10-Q\)](#)